Dabrafenib Active in Rare NSCLC Subtype.

Abstract excerpt

Results from a phase II trial show that the BRAF inhibitor dabrafenib has significant single-agent activity in patients with advanced non-small cell lung cancer harboring the BRAF V600E mutation. However, data from another arm of the study suggest that combining dabrafenib with a MEK inhibitor may be a more effective treatment strategy for these patients.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to Clinical Trials, Phase II as Topic
• Share to Disease-Free Survival